S everal vaccines and drugs for preventing the spread of HIV are showing signs of success in clinical trials, three decades after scientists began the search. But some researchers fear that progress will stall without a coordinated strategy to ensure that the most promising therapies to prevent infection win support from policymakers and reach the people who need them.
A meeting convened by the World Health Organization (WHO) in Geneva, Switzerland, from 28 February to 1 March aims to address a lack of long-term thinking about the factors -such as cost and ease of use -that can determine whether a vaccine or other preventive therapy succeeds in reducing disease. Some HIV researchers argue that they should study these issues now, while clinical trials of potential vaccines and drugs are ongoing, to avoid delays in delivering effective therapies to people at risk of infection. Many hope that the WHO meeting will trigger broader discussions about how to support such research given limited resources, and how to prioritize therapies in development.
Waiting to conduct these kinds of studies until trials are finished prolongs the time for a preventive therapy to reach people. In the meantime, the epidemic worsens. Worldwide, about 1.8 million people contracted HIV in 2016. "You need to have a good idea about where you want to end up and all of the steps you need to make to get there, " says Mark Feinberg, president of the International AIDS Vaccine Initiative in New York City.
But it is not clear who would make decisions about which projects to prioritize, or when the choices would be made.
Some 25,000 people around the world are participating in clinical trials of treatments to prevent HIV infection. Twelve late-stage trials worldwide are testing experimental vaccines; these include a 2,600-person study in southern Africa of a vaccine designed to block multiple strains of the virus. Others are assessing the potential of proteins called broadly neutralizing antibodies, which might stop HIV from infecting immune cells. And a pair of phase III trials has enrolled 7,700 people to test whether injections of the drug cabotegravir can prevent HIV infection for two months at a time.
DELIVERY CONCERNS
At the meeting, researchers, policymakers and HIV activists will discuss stumbling blocks that have limited the use of potent vaccines and treatments against other diseases, such as high costs and cumbersome delivery requirements. Because no therapy has approached 100% protection against HIV, regulators face tough decisions when considering the cost and effort of delivering treatment to people at risk. In 2009, for example, a phase III study of the most promising vaccine identified so far found that it reduced a person's risk of contracting HIV by only one-third (S. Rerks-Ngarm et al. N. Engl. J. Med. 361, 2209 -2220 2009 ). Health authorities did not recommend it for widespread use.
A modified version of that vaccine is now being tested in 5,400 people in South Africa, and researchers hope that it will reduce a person's chance of contracting HIV by at least 50%. But even if the trial succeeds, the expense and difficulty of administering the vaccine, which must be given as six injections over 18 months, could make it a hard sell to policymakers and funders. Health-care workers around the world struggle to persuade healthy people to get one-time shots that are highly effective against other deadly diseases.
Similar concerns surround the antibodies in development, because they are given as intravenous infusions, and it is unclear how long treatment must continue to prevent HIV. The antibodies are also relatively expensive to make. Eventually, scientists must be prepared to choose which projects to stall, and which to supplement with studies aimed at developing cheaper, easier ways of administering a given therapy, says Mitchell Warren, executive director of AVAC, an HIV-prevention advocacy
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HIV-vaccine strategy sought
Therapies to prevent infection advance in a crowded field. nature.com/nature/ podcast organization in New York City. Money is limited, as is the pool of people available for clinical trials, which become larger and more complex as a vaccine or antibody treatment progresses towards the market. "We will need prioritization, " Warren says. "That view needs to be driven by science and financial realities, and the decision process needs to be clear and transparent. "
Another issue facing researchers is how to improve the likelihood that people at risk of HIV infection will take preventive treatments.
Success is not guaranteed: Truvada, a daily pill for preventing HIV infection, has not reduced the number of new HIV cases globally since regulators approved it six years ago. In eastern and southern Africa, for instance, young women rarely take the drug, even though they account for 26% of the region's new infections. Tian Johnson, founder of the African Alliance for HIV Prevention in Johannesburg, South Africa, says that researchers did not adequately consider how poverty, pregnancy, discrimination and abuse might affect whether young women at risk are likely to seek out Truvada. "If you disregard the complexity of a woman's daily life and reality, you put at risk the millions of dollars you invest in developing a product, " Johnson says.
Despite the challenges ahead, the fact that these discussions are happening is an important step forward, says Feinberg. "You can't keep your head in the sand, " he says. "You need to work ahead and think of ways that we as a research-development community can solve these problems -and they are solvable. " ■
CORRECTION
In saying that everyday atomic hearts have equal protons and neutrons, the News story 'Physicists plan first antimatter road trip' (Nature 554, 412-413; 2018) didn't take account of the fact that some elements, such as hydrogen and lithium, have uneven numbers of protons in their most abundant form.
The News Feature 'The entangled web' (Nature 554, 289-292; 2018) 
BY D E C L A N B U T L E R
R esearchers have developed an automated technique that they say can quickly detect duplicate images among hundreds of thousands of papers. If it proves successful, the software could make it easy for editors to screen images before publication -something that currently requires great effort and is done by only a few publications.
Daniel Acuna, a machine-learning researcher at Syracuse University in New York, and his two colleagues described their algorithm on 22 February (D. E. Acuna et al. Preprint at bioRxiv http://dx.doi. org/10.1101/269415; 2018).
Acuna says he isn't making the full algorithm public, because that could trigger false allegations. Instead, his team plans to license it to journals and research-integrity offices. Lauran Qualkenbush, director of the Office for Research Integrity at Northwestern University in Chicago, Illinois, and vice-president of the US Association of Research Integrity Officers, says she has discussed the approach with Acuna. "It would be extremely helpful for a research-integrity office, " she says.
In early 2015, Acuna's team used the algorithm to extract more than 2.6 million images from the 760,000 articles then in the openaccess subset of the PubMed database of biomedical literature. These included micrographs of cells and tissues, and gel blots. The algorithm then zoomed in on the most feature-rich areas -where colour and greyscales vary most -to extract a characteristic digital 'fingerprint' of each image.
The researchers only compared images across papers from the same first and corresponding authors, to avoid the computational load of comparing every image against every other one. But the system could pick up potential duplicates even if they had been rotated, resized or had their contrast or colours changed. The trio then manually examined a sample of around 3,750 of the flagged images to judge whether the duplicates were suspicious or potentially fraudulent. On the basis of their results, they predict that 1.5% of the papers in the database would contain suspicious images, and that 0.6% of the papers would contain fraudulent images.
The researchers haven't been able to benchmark the accuracy of their algorithm, says Hany Farid, a computer scientist at Dartmouth College in Hanover, New Hampshire -because there isn't a database of known duplicate or non-duplicate scientific images against which they could test the tool.
At present, many journals check some images, but relatively few have automated processes. For instance, Nature runs random spot checks on images in submitted manuscripts. (Nature's news team is editorially independent of its journal team.)
To detect image reuse across the literature, publishers would need to create a shared database of all published images against which articles submitted for publication could be compared, says IJsbrand Jan Aalbersberg, head of research integrity at the Dutch publishing giant Elsevier.
There are currently no plans for a publisher-wide system for image checking, but that is partly because the technologies are not yet mature, says Ed Pentz, executive director of Crossref, a non-profit collaboration of 10,000 publishers. Crossref runs a service that enables publishers to routinely screen submitted manuscripts for plagiarism. Elsevier says it would support such an initiative for images. Two years ago, the company set up a 3-year, €1-million (US$1.2-million) par tnership with Humboldt University in Berlin to study article mining and to identify research misconduct. On 25 January, the project announced that it intends to create a database of images from retracted publications. Such a data set would provide a bank of test images for researchers developing automated screening of images in publications. ■ 
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Duplicated images could soon be identified by an automated test
